About MATRIX Project

The Microbicide Research and Development to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence (MATRIX) project was a five-year (2021–2026) project funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID). It was a consortium of 20 organizations and product developers working together to inform and accelerate early R&D for new HIV products by providing an innovative ecosystem in which early-stage HIV technologies can be advanced. The investigators and partners in the United States and the global South are experts in product development, clinical trials, social and behavioural research and market and business case development.

 

The main objective and aim of the project was to develop a range of acceptable, affordable, scalable, and deliverable products to meet the unmet needs of women at risk of HIV. The project has 5 hubs responsible for the different activities. Pangaea Zimbabwe (PZ) was in the Design to Delivery Hub (D2D) which is the MATRIX collaborative’s consultative working group for coordinated engagement of a range of end users, service providers, key influencers and other local partners who can provide insight into the uptake, roll-out and acceptability of different HIV prevention options.

Engagement activities were conducted with potential women end-users, key influencers, including male partners, and healthcare providers (HCPs) to understand their values, preferences, and experiences regarding emerging HIV prevention products. Three engagement sessions were conducted with each of four subgroups of women, reaching a total of 118 participants, to gather feedback on five dual-purpose HIV and pregnancy prevention products. Findings revealed strong interest in dual prevention products due to their convenience, cost-saving benefits, and reduced user burden, with discretion emerging as a key preferred feature.

Additionally, a workshop involving 27 healthcare providers, comprising 20 nurses, four pharmacists, and three doctors, explored their perceptions and preferences regarding novel HIV prevention products. Recruitment was supported by roadshows conducted at an urban clinic, a district hospital, and a private hospital. Healthcare providers expressed interest in dual prevention products because of their convenience and potential to reduce provider and user burden, while emphasizing the need for comprehensive provider training and the importance of health facilities as primary access points for these products. These engagements generated valuable insights to inform product development, demand creation, and future implementation strategies.

Surveys were conducted with diverse groups of women to gain a deeper understanding of end-user acceptability and preferences for different classes of HIV prevention products, including on-demand, monthly, and longer-acting options. A total of 518 women aged 18–45 years were recruited from rural and urban communities, representing a wide range of socioeconomic backgrounds. Participants completed interviewer-administered, tablet-based surveys to share their perspectives on emerging HIV prevention products. Findings highlighted varying levels of acceptability and preferences, with some women expressing enthusiasm for certain products while rejecting others. These insights underscore the importance of developing a diverse range of HIV prevention options that respond to women’s different needs, preferences, and circumstances.

Engagement with diverse stakeholders, including women end-users, healthcare providers, and male partners, was undertaken to establish and maintain a consumer panel database for gathering ongoing feedback on emerging HIV prevention technologies. Panel members are segmented into different subgroups to facilitate targeted engagement through tailored quick polls administered via SMS and WhatsApp using a bulk messaging platform. To date, three quick polls have been conducted with potential women end-users, reaching a total of 621 women. The polls explored preferences for colour combinations of a dual-purpose vaginal ring, packaging options for a fast-dissolving vaginal insert, and the acceptability of a dual-purpose prevention product that may cause menstrual changes. These engagements provide valuable insights into user preferences and acceptability, supporting the development of HIV prevention products that are responsive to the needs and expectations of potential end-users.

The first Data-to-Impact and Use (D2IU) session was conducted to share synthesized findings from previous engagements, identify existing gaps, and inform future project activities. The session brought together 46 women and seven healthcare providers who had participated in earlier project activities. Discussions highlighted women’s preference for discreet HIV prevention products with minimal side effects. Participants also expressed interest in products that could potentially be accessed over the counter, reducing the need for visits to public health facilities while easing the burden on healthcare providers. These insights reinforced the importance of developing accessible, convenient, and user-centred HIV prevention options that respond to women’s needs and preferences while supporting efficient healthcare service delivery.

The Demand-to-Delivery (D2D) cross-pillar team conducted an HIV prevention landscape analysis to assess the acceptability of and preferences for biomedical HIV prevention products among women in sub-Saharan Africa. The analysis involved a systematic review of existing evidence to generate insights that would inform the development of novel, user-centred HIV prevention technologies. Findings from the analysis were consolidated into a manuscript that was subsequently published in the AIDS and Behavior journal, contributing to the growing body of evidence on women’s HIV prevention needs and preferences. Three Pangaea Zimbabwe (PZ) MATRIX staff members contributed as co-authors, with one serving as the lead author, highlighting PZ’s contribution to research, evidence generation, and knowledge dissemination within the MATRIX initiative.

There was significant acceptability for new HIV prevention products that were in the MATRIX development pipeline from potential women end-users and health care providers. Preferences for the products depended on the product characteristics, the social and structural context.

Focus Area

Specifically, PZ was in the End-user acceptability, D2D Pillar 1, which included 3 global South countries namely Kenya (KEMRI), South Africa (Wits RHI and CAPRISA), and Zimbabwe (PZ), and one global North partner, FHI 360, based in the United States. The Pillar 1 goal was to generate and collate insights on the acceptability of and preference for HIV prevention products from end-users including women in communities with high HIV rates, key influencers such as male partners, health care providers and community leaders. Project activities intend to generate rapid feedback about different products and product classes about their acceptability of different attributes and overall interest in using these products to use product-specific decisions related to target product profiles and to identify research and development needs and priorities.

  • Years implementation period from 2021-2025

  • Sites: Bulawayo, Chitungwiza, Harare, Mazowe, Plumtree

  • K+

    Participants Reached

  • +

    Women participated in the Rapid Response Network

MATRIX Resources can be found here: MATRIX Resources